Developments in the Management of Myelofibrosis After ASH 2024 - Episode 2

Challenges With Low-Dose Ruxolitinib in Myelofibrosis

Sangeetha Venugopal, MD, MS, discusses challenges with low-dose ruxolitinib in myelofibrosis.

EP. 1: Treatment Trends: JAK Inhibitor Selection in Myelofibrosis
Now Viewing
EP. 2: Challenges With Low-Dose Ruxolitinib in Myelofibrosis
EP. 3: The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis
EP. 4: PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis
EP. 5: Data for Navtemadlin in Relapsed/Refractory Myelofibrosis
EP. 6: Other Notable Myelofibrosis Data From ASH 2024

Related Content:

Developments in the Management of Myelofibrosis After ASH 2024Sylvester Comprehensive Cancer Center, University of MiamiMyeloproliferative Neoplasms
Other Notable Myelofibrosis Data From ASH 2024
Data for Navtemadlin in Relapsed/Refractory Myelofibrosis
PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis